From: Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)
Study
BHV-3000-201
Treatment
Rimegepant
Mean age (years)
43.2
Female (%)
91.1%
Mean MMD at baseline (mean)
10.9